WHO preferred product characteristics for herpes simplex virus vaccines
Development of one or more herpes simplex virus (HSV) vaccines is an important objective for sexual and reproductive health worldwide. WHO preferred product characteristics (PPCs) provide strategic guidance as to WHO’s preferences for new vaccines in priority disease areas. PPCs are intended to encourage innovation and development of vaccines for use in settings most relevant to the global unmet public health need. HSV vaccine PPCs describe global public health goals for HSV vaccines and preferred parameters pertaining to vaccine indications and target populations, safety and efficacy considerations, research and development, and immunization strategies.